Table 2.
Top canonical pathways affected in GalT-II-deficient skin fibroblasts.
| Name | P-value | Ratio⁎ | DEGs |
|---|---|---|---|
| Axon guidance | 3.30E-05 | 10/129 | EFNB2, NTN1, UNC5B, EPHA2, SEMA3A, CXCL12, MET, SEMA6A, SEMA5A, PLXNA2 |
| Cell adhesion molecules | 1.72E-04 | 9/34 | NLGN1, NCAM2, NLGN4X, CLDN11, CNTN1, HLA-DPA1, CDH2, JAM2, CD274 |
| Cytokine–cytokine receptor interaction | 8.04E-04 | 12/263 | CCL2, TNFRSF19, PDGFC, TNFSF10, KIT, IL1R1, CXCL6, CXCL1, CXCL12, CCL28, TNFSF4, MET |
| Calcium signaling pathway | 0.002 | 9/182 | GRPR, ADCY4, CHRM2, AVPR1A, AGTR1, ADNRB, PLCD3, OXTR, PDE1C |
| ECM–receptor interaction | 0.009 | 5/84 | CD47, COL5A1, SPP1, ITGA11, COMP |
| Focal adhesion | 0.03 | 7/203 | PDGFD, PDGFC, COL5A1, SPP1, MET, ITGA11, COMP |
| TGF-beta signaling pathway | 0.04 | 5/87 | ID1, GDF6, SMAD7, COMP, BAMBI |
| Neuroactive ligand–receptor interaction | 0.04 | 8/256 | GRPR, CHRM2, GRIK2, AVPR1A, AGTR1, EDNRB, RXFP1, OXTR |
⁎
Input genes/genes in pathway, the down-regulated genes are reported in bold.